Start-up Australia invests in bone-building tech
04 April, 2005 by Renate KrelleVenture capital fund Start-up Australia Ventures has invested AUD$3 million in junior biotech Caldeon, which is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
Biogen withdraws 2005 financial forecast
04 April, 2005 by Staff WritersBiogen has withdrawn its 2005 earnings forecast as it can no longer count on revenue from its suspended multiple sclerosis drug Tysabri.
Pfizer, Prana big winners in latest P3 round
01 April, 2005 by Renate KrelleFour Queensland-based companies, two Victorian biotechs and the NSW-based arm of an international pharmaceutical firm have received a total of AUD$46 million under the federal government's pharmaceutical partnerships program, known as P3.
In brief: Starpharma, Proteome Systems, Meditech, C3, Biodiem
31 March, 2005 by Staff WritersStarpharma (ASX: SPL, USOTC:SPHRY) has appointed former Cerylid Biosciences chief executive officer Dr Jackie Fairley to the newly created position of chief operating officer. Fairley will begin her role with Starpharma toward the middle of 2005.
Epitan plans AIM listing
31 March, 2005 by Staff WritersMelbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
Phylogica defies IPO blues
30 March, 2005 by Renate KrellePerth-based functional proteomics company Phylogica (ASX: PYC) has defied recent biotech trends, with shares in the company opening today 37 per cent above their issue price of $0.20. At time of writing shares had slipped slightly and were trading at $0.25.
Norwood raises $5.8m in US
29 March, 2005 by Melissa TrudingerNorwood Abbey (ASX:NAL) has raised AUD$5.8 million (US$4.5 million) through a placement to three US institutional investors. The company may also receive a further $6 million in additional equity investment from the same investors within the next six months.
In brief: C3, DNT, Starpharma, synchrotron
29 March, 2005 by Staff WritersClinical Cell Culture (C3, ASX:CCE) has received its first batch of stocking orders for its ReCell device used to treat small burns and scars from its European distributor network.
Medsaic sets out to profile leukaemia
29 March, 2005 by Renate KrelleA Sydney company is hoping pathologists will be making room next to their flow cytometers for a new technology which provides doctors with a detailed profile of leukaemias and lymphomas, setting the scene for tailored treatment.
Phylogica IPO closes oversubscribed
24 March, 2005 by Melissa TrudingerPerth-based functional proteomics company Phylogica has closed its IPO after raising $5 million through the sale of 25 million shares at $0.20.
UK scientists to probe need for monkey research
24 March, 2005 by Staff WritersBritish scientists are to take the world's first hard look at whether monkeys should continue to be used in biological and medical research.
Benitec licenses technology to French transgenic rat firm
22 March, 2005 by Graeme O'NeillBenitec (ASX:BLT) has granted a worldwide, non-exclusive commercial licence to French company genOway to develop transgenic rodents with Benitec's proprietary DNA-directed RNA-inferference technology (ddRNAi).
In brief: Recell, Avexa, CBio, Eqitx
22 March, 2005 by Staff WritersClinical Cell Culture (C3, ASX:CCE) has received CE Mark approval from European certification authority and notified body SGS for its Recell medical device, clearing the way for first sales of the product to plastic and cosmetic surgeons.
Tissue Therapies' Vitro-Gro heals burns without scarring
22 March, 2005 by Graeme O'NeillBrisbane's Tissue Therapies (ASX:TIS) announced today that trials of its Vitro-Gro wound-healing technology at the Royal Children's Hospital show it not only accelerates the healing of serious burns, but leaves no scarring.
ES cell research opponents cheer Griffith research
22 March, 2005 by Graeme O'NeillOpponents of embryonic stem cell research have leaped to congratulate Griffith University scientists, who yesterday announced details of research in which differentiated cells were successfully grown from adult stem cells.
